University of Lisbon-founded biotherapeutics developer is targeting infectious, metabolic and intestinal conditions, and has collected $2.8m from a fund run by Seventure Partners.
Neurimm Therapeutics, a France-based biotherapeutics developer spun out of University of Lisbon, received €2.5m ($2.8m) in seed funding today from venture firm Seventure Partners’ Health for Life vehicle.
Founded in 2018, Neurimm Therapeutics is developing drugs which regulate a group of innate immune cells, known as innate lymphoid cells (ILCs), together with neuronal cell signalling to combat diseases caused or mediated by the immune system, including infections, inflammation and metabolic diseases.
The approach combines immune system research with advances in the understanding of microbiomes, collections of microorganisms such as bacteria which inhabit the body.
The company is initially targeting two ILC subtypes; ILC2, which it believes plays a crucial role in infections and metabolic diseases, and ILC3, cells which fortify the lining of the gut potentially useful in treating gut inflammation and inflammatory bowel disease.
Neurimm Therapeutics extends research from the Champalimaud Clinical Centre in the immunophysiology lab of Henrique Veiga-Fernandes, an alumnus of University of Lisbon.
